NOV 13, 2019 09:27 AM PST

The Side-Effects to A Common Blood Cancer Drug

WRITTEN BY: Nouran Amin

In a study published in Scientific Reports, a popular cancer drug, known as ruxolitnib, was found to cause an increased weight gain as well as an increase in liver enzymes and systolic blood pressure.

“Weight gain with ruxolitinib has previously been reported in clinical trials, but our study provides real-world experience regarding the extent of that weight gain,” said Emily J. Gallagher, MD, PhD, the study’s lead author and Assistant Professor of Medicine (Endocrinology, Diabetes and Bone Disease) at the Icahn School of Medicine at Mount Sinai, specializing in onco-endocrinology, the treatment of endocrine complications of oncology treatments. “We recommend that patients who go on this medication and do have an increase in weight get a full metabolic evaluation.”

Researchers from Icahn School of Medicine at Mount Sinai reported in their study that the FDA-approved ruxolitinib, which was the first and most widely prescribed in treating blood cancers, holds strong metabolic effects. Ruxolitinib treats the particular blood cancer group known as myeloproliferative neoplasms (MPNs), which includes myelofibrosis and polycythemia vera. The drug blocks the enzyme Janus kinases (JAK) ½ resulting in the inhibition of blood cell production. Although previous studies have noted the side-effects, researchers are now beginning to understand the long-term consequences of cancer therapeutics on metabolic health.

Learn more about the mechanism of action:

“In contrast to the perception of many health care providers, patients are not going from being underweight to being a normal weight. Instead, a significant number of patients are developing obesity. Based on these results, physicians should be aware of the potential effects, and counsel patients accordingly,” said Dr. Gallagher.

Source: Mount Sinai Health

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
DEC 12, 2019
Drug Discovery & Development
DEC 12, 2019
Promising Drug for Prostate Cancer
Using high-throughput screening methods, cancer researchers from the UK have identified some promising drug candidates to test thousands of molecules. Spec...
DEC 12, 2019
Drug Discovery & Development
DEC 12, 2019
Common Therapeutic Can Treat Bleeding Associated with Traumatic Brain Injury
An inexpensive and accessible drug was found to reduce rates of mortality associated with traumatic brain injury (TBI) patients by 20%. TBI is a major caus...
DEC 12, 2019
Technology
DEC 12, 2019
New Encapsulation Technology
Research at the University of Waterloo has concluded new encapsulation technology that can offer an inexpensive, and effective method for coating liquid me...
DEC 12, 2019
Cannabis Sciences
DEC 12, 2019
Cannabis Can't Simply Replace Opioids for Pain Management
According to the research, cannabis is not effective when it comes to treating individuals struggling with opioid use disorder. While some may have conside...
DEC 12, 2019
Drug Discovery & Development
DEC 12, 2019
Darobactin: Promising New Drug to Combat Antibiotic Resistance
Every year, around 700,000 people are estimated to die from drug-resistant infections thanks to our overuse of antibiotics both in agriculture and medicine...
DEC 12, 2019
Health & Medicine
DEC 12, 2019
Federal Restrictions Make It Hard For Cannabis Researchers
With marijuana use becoming more popular in aiding health, scientists race to find clarity around its health benefits and risks. Since the legalization of...
Loading Comments...